Table 2.
The number of patients in the study sample at each stage of the CrAg Screening Cascade, stratified by urban/rural status of the health facility where their record was reviewed and overall (n = 359)
| Stage on the CrAg cascade | Location of site | P-value | ||
|---|---|---|---|---|
| Urban | Rural | Overall | ||
| Number: Proportion % (95% CI) | Number: Proportion % (95% CI) | Number: Proportion % (95% CI) | ||
| Patients with CD4 ≤ 100 μ/ml | 209 (58.2) | 150 (41.8) | 359 (100.0) | |
| Patients with CrAg screen | 170: 81.3 (75.4–86.4) | 85: 56.7 (48.3–64.7) | 255: 71.0 (66.0–75.7) | < 0.001 |
| Patients screened for CrAg within 7 days of a CD4 test | 138: 81.2 (74.5–86.8) | 72: 84.7 (75.3–91.6) | 210: 82.4 (53.4–63.8) | 0.489 |
| Patients with CrAg screen contacted with results | 170: 100.0 (97.9–100.0) | 82: 96.5 (90.0–99.3) | 252: 98.8 (96.6–99.8) | 0.014 |
| Patients with a CrAg positive result | 48: 28.2 (21.5–35.0) | 8: 9.4 (4.2–17.7) | 56: 22.0 (17.0–27.5) | 0.001 |
| Patients screen for signs and symptoms of CNS infection | 43: 89.6 (77.3–96.5) | 7: 87.5 (47.3–99.7) | 50: 89.3 (78.1–96.0) | 0.860 |
| Patients in whom a lumbar puncture was done | 39: 81.3 (67.4–91.1) | 0: 0 (0.0–0.0) | 39: 69.6 (55.9–81.2) | |
| Patients started on pre-emptive fluconazole therapy | 39: 81.3 (67.4–91.1) | 8: 100.0 (63.1–100.0) | 47: 83.9 (71.7–92.4) | 0.181 |
| Patients started on fluconazole that were still receiving pre-emptive fluconazole at 6 months | 5: 12.8 (4.5–28.8) | 3: 37.5 (8.5–75.5) | 8: 17.0 (7.6–30.8) | 0.108 |
| Patients who were started on ART | 183: 87.6 (82.3–91.7) | 149: 99.3 (96.3–100.0) | 332: 92.5 (89.2–95.0) | < 0.001 |
| Patients who were started on ART prior to CrAg screening | 130: 71.0 (63.9–77.5) | 53: 35.6 (27.9–43.8) | 129: 38.9 (33.6–44.3) | < 0.001 |
| Patients with a CD4 ≤ 100 μ/ml that were reportedly alive at the time of data collection | 110: 52.6 (45.6–59.6) | 103: 68.7 (60.6–76.0) | 213: 59.3 (54.1–64.5) | 0.002 |